NASDAQ, SGMO - Sangamo Therapeutics
We are a leader in the research, development and commercialization of zinc
finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins, and
have used our knowledge and expertise to develop a proprietary technology
platform. ZFPs can be engineered (see Fig. 1) to make ZFP transcription factors,
or ZFP TFs ?, proteins that can be used to turn genes on or off, and ZFP
nucleases, ZFNsTM, proteins that enable us to modify DNA sequences in a variety
of ways. As ZFPs act at the DNA level, they have broad potential applications in
several areas including human therapeutics, plant agriculture, research reagents
and cell-line engineering.
The main focus for our company is the development of novel human therapeutics
and we are building a pipeline of ZFP Therapeutics?. ...
Read SEC Filing on NASDAQ.com »